Aldometanib | Aldolase inhibitor

CAS:
 2904601-67-6
Catalog Number:
 10-4445

Available Options

Size:PriceQuantity 
5 mg$65.00
25 mg$225.00
Request Quote / Bulk / Custom Size
Product Inquiry

Aldometanib (2904601-67-6) inhibits (IC50 = 50 µM) aldolase by blocking its binding with fructose-1,6-bisphosphate (FBP).1 It activates lysosomal AMPK and mimics a cellular state of glucose starvation. Aldometanib alleviated fatty liver and nonalcoholic steatohepatitis in mice and extended lifespan. It mitigated inflammation and oxidative stress damage in LPS-treated lung fibroblasts and also inhibited NLRP3-mediated pyroptosis.2  Aldometanib inhibited hepatocellular carcinoma in mice in an AMPK-dependent manner.3 It rebalanced the tumor microenvironment allowing cytotoxic CD8+ T cells to infiltrate tumor cells.

References/Citations:

  1. Zhang et al. (2022), The aldolase inhibitor aldometanib mimics glucose starvation to activate lysosomal AMPK; Nat. Metab., 4 1369
  2. Shao et al. (2025), Aldometanib mitigates LPS-induced lung fobroblasts injury through the activation of AMPK-mediated signaling pathways; Toxicon, 265 108489
  3. Hu et al. (2025), Glucose starvation mimetic aldometanib removes immune barriers permitting mice with hepatocellular carcinoma to live to normal ages; Cell Res., 35 934
2904601-67-6, aldolase inhibitor, aldometanib, Aldometanib supplier
CAS:
2904601-67-6
Catalog Number:
10-4445
Activity:
Aldolase inhibitor
Chemical Names:
1-[(2,6-Dichlorophenyl)methyl]-3-hexadecyl-2-methylimidazol-1-ium iodide
Alternate Name:
LXY-05-029
Molecular Weight:
593.46
Molecular Formula:

C27H43Cl2IN2

Solubility:
Soluble in DMSO (>100 mg/ml)
Physical Properties:
White to off-white solid
Purity:

>98% TLC
NMR: (Conforms)

Storage Temperature:
-20°C
Stability:
Stable for up to 2 years when stored as supplied @ -20°C. Solutions in DMSO may be stored at -20°C for up to 3 months.
Shipping Code:
RT

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

Aldometanib (2904601-67-6) inhibits (IC50 = 50 µM) aldolase by blocking its binding with fructose-1,6-bisphosphate (FBP).1 It activates lysosomal AMPK and mimics a cellular state of glucose starvation. Aldometanib alleviated fatty liver and nonalcoholic steatohepatitis in mice and extended lifespan. It mitigated inflammation and oxidative stress damage in LPS-treated lung fibroblasts and also inhibited NLRP3-mediated pyroptosis.2  Aldometanib inhibited hepatocellular carcinoma in mice in an AMPK-dependent manner.3 It rebalanced the tumor microenvironment allowing cytotoxic CD8+ T cells to infiltrate tumor cells.

References/Citations:

  1. Zhang et al. (2022), The aldolase inhibitor aldometanib mimics glucose starvation to activate lysosomal AMPK; Nat. Metab., 4 1369
  2. Shao et al. (2025), Aldometanib mitigates LPS-induced lung fobroblasts injury through the activation of AMPK-mediated signaling pathways; Toxicon, 265 108489
  3. Hu et al. (2025), Glucose starvation mimetic aldometanib removes immune barriers permitting mice with hepatocellular carcinoma to live to normal ages; Cell Res., 35 934

STEM CELL

BOGO